P PRIMESTOCKFINDER.COM

NEU Shares Neuren Pharmaceuticals Limited

BUY ASX · ASX
$18.70 +0.27% Prices as of close 2026-10-26

Commercial neurodevelopment therapies generate recurring revenue and pipeline optionality.

Future value: $25.91 (+38.57%) · 6-12 months · analyst consensus

Signal breakdown

  • ▸Commercial revenue base and analyst target above market price.
  • ▾Below 50-day MA (-8.73%)
  • ▸Above 200-day MA — long-term uptrend
  • ▸~39% upside to price target

Is NEU a buy right now?

Trend: NEU is trading below the 50-day average (-8.58%), RSI 44 — neutral momentum, with a 3-month return of +6.69%.

Valuation & quality: Neuren Pharmaceuticals Limited trades on a trailing P/E of 124.3, forward P/E 31.3, price-to-book 7.09; fundamentals show net margin 29.1%, return on equity 6.2%, revenue growth 17.3% year on year.

Analyst consensus: 6 analysts have a mean 12-month price target of A$25.91 (+38.6% vs the last close; range A$24.50 – A$28.90), consensus rating “strong buy”.

Income: trailing dividend yield 1.53%.

Our screen: BUY (score 3) — Commercial neurodevelopment therapies generate recurring revenue and pipeline optionality.

Computed from end-of-day data; not personal advice.

Our track record with NEU

Our simulated $10,000 funds have traded NEU 2 times — 0 of 2 closed trades profitable.

FundBoughtSoldReturn
ASX High-risk2026-08-22 @ $22.462026-08-24 @ $22.45 · AI review sell-0.04%
ASX High-risk2026-07-01 @ $16.972026-08-03 @ $16.97 · Monthly rebalance+0.00%

Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.

12-month price chart

23.6 11.3 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-08 → 2026-10-26 (AUD). Range 11.3 – 23.6.

Monthly returns

Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
-5.40%+1.00%+16.70%+22.10%+1.40%+9.70%+3.10%-8.40%

Fundamentals

Market cap
$2.36B
P/E (ttm)
124.3
Forward P/E
31.3
EPS (ttm)
$0.15
Price / book
7.09
Beta
1.57
Net margin
29.1%
ROE
6.2%
Revenue growth
17.3%
Earnings growth
-67.3%
Revenue (ttm)
$69.5M
Free cash flow
$-13,546,250
Dividend yield
1.53%
52-wk range
$11.00 – $23.76
Volume
444,930
Avg volume (3m)
472,655

Analyst price target

Mean target
$25.91
Low
$24.50
High
$28.90
Analysts
6
Consensus
STRONG BUY

Technical signals

RSI (14)
44.0
vs 50-day MA
-8.58%
1-mo return
-5.90%
3-mo return
+6.69%
Volume z-score
0.77

About Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.

Sector: Healthcare · Industry: Biotechnology · Australia · Website

Related Biotech picks

CSL.AXCSL LimitedMSB.AXMesoblast LimitedIMR.AXImricor Medical SystemSLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics DXB.AXDimerix LimitedNYR.AXNyrada Inc.ACW.AXActinogen Medical Limi

Browse: all ASX stocks · Biotech picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.